

SUMMARY

Problems associated with physical dependence and abuse of benzodiazepines by a small percentage of patients have reduced their popularity from the most commonly prescribed psychoactive drug in the 1970s to being prescribed for mainly short periods. Patients who benefit from long-term benzodiazepine use are nearly ignored by the medical community as a whole. This article details what patient population can improve from long-term benzodiazepine therapy, the risks and benefits of treatment, and how to select appropriate candidates.

RÉSUMÉ

Les problèmes reliés à la dépendance physique et à l'abus des benzodiazépines par un faible pourcentage de patients ont contribué à la baisse de popularité qu'elles ont connue dans les années 1970 alors qu'elles occupaient le premier rang des médicaments psycho-actifs prescrits; actuellement, on les prescrit surtout à court terme. Globalement, la communauté médicale ignore pratiquement les patients qui bénéficieraient des benzodiazépines à long terme. Cet article décrit quelle population de patients aurait avantage à recevoir un traitement de benzodiazépines à long terme, les risques et les avantages de ce traitement, et propose une méthode appropriée pour identifier ceux qui sont à risque d'abuser d'une telle médication.

Can Fam Physician 1992;38:149-153.

Long-Term Use of Benzodiazepines

Implications and guidelines

NICHOLAS L.S. POTTS, MD
K. RANGA R. KRISHNAN, MD

BENZODIAZEPINES WERE INTRODUCED in the early 1960s and were enthusiastically received as the new miracle drugs to treat anxiety disorders. Compared with other available drugs, ie, barbiturates, they were safer, offering little chance for a lethal overdose, were less addictive or prone to abuse, and were more effective anxiolytics. This led to a rapid shift by the medical community to prescribing benzodiazepines, which peaked in 1973, when benzodiazepines totalled 53% of all prescribed psychoactive drugs and about 6% of all prescriptions.¹

Concerns, however, soon arose about addiction and abuse, especially problems with withdrawal. By 1982 prescription rates had fallen by 30%. Since then, even with the introduction of newer, more effective benzodiazepines, like alprazolam (Xanax), only limited recovery of the prescriptions has occurred.²

The aim of this article is twofold: 1) to address some of the concerns of the medical community over the long-term use of benzodiazepines and 2) to help identify patients who will profit from their use and point out

Dr Potts is a Resident in Psychiatry at the Department of Psychiatry, Duke University Medical Center, Durham, NC. **Dr Krishnan** is Medical Director of the Affective Disorders Unit and is Associate Professor of Psychiatry at the Department of Psychiatry, Duke University Medical Center, Durham.

those at risk of abusing the drugs. It is important for physicians to be aware of these points so they are more comfortable prescribing the drugs to reduce patients' symptoms. Family physicians are the largest group of physicians treating anxiety disorders and the largest prescribers of benzodiazepines, whereas psychiatrists prescribe less than 20% of all anxiolytics in this country.³

Anxiety disorders

A recent survey by the National Institutes of Mental Health showed that the 6-month prevalence rate of anxiety disorders among the adult population in the United States was 8.3%. Only 23% of these individuals had received any form of treatment.⁴ This survey makes it evident that anxiety disorders, the most common psychiatric problem in the community, usually go untreated. The anxiety disorders that appear to benefit from long-term benzodiazepine treatment are panic disorder, with or without agoraphobia, agoraphobia, generalized anxiety disorder, and social phobia.

Panic disorder is associated with severe episodes of anxiety, which occur spontaneously and without provocation. Common symptoms of these attacks include shortness of breath, dizziness, palpitations, sweating, tingling or numbness, and chest pains or tightness. These attacks can also be associated with a fear of doing something "crazy" or a fear of dying. If persons with panic disorder begin to avoid places

or situations that they believe cause their panic attacks, they have developed panic attacks with agoraphobia.

Agoraphobia, however, can occur without panic attacks preceding it. In this instance patients fear being in places or situations from which escape might be difficult or embarrassing. They can also fear having something embarrassing or incapacitating occur to them in front of others, ie, vomiting, fainting, or loss of bladder or bowel control. Examples of common phobias are being outside of the home alone; being in a crowd or standing in a line; and being in a bus, train, or car or driving through a tunnel or over a bridge.

Generalized anxiety disorder is characterized by excessive or unrealistic worry about two or more of life's main concerns (eg, child, family, finances) that is persistent and distressing. These fears are associated with symptoms of motor tension, autonomic hyperactivity, and hypervigilance.

Social phobia, the last of this group of disorders, is characterized by fears of embarrassing or humiliating oneself in front of others by saying or doing the wrong thing. The most frequently avoided situations include speaking in public, meeting strangers, eating or drinking in public, urinating in a public lavatory, and situations in which the individual could face possible criticism or humiliation. All of these disorders are associated with overwhelming episodes of anxiety and involve the development of phobic and avoidance patterns.

Over the years, psychiatry has placed greater emphasis on properly defining illness and has spent more time observing the natural history of illnesses. Consequently it is now clear that anxiety disorders follow a chronic course and place the patient at increased risk of social isolation, depression, and alcohol abuse, and in some cases they end in suicide.⁵ Furthermore, the symptoms can be eradicated by appropriate therapy but can return rapidly upon cessation of treatment.^{6,7} Before the onset of the disorder, however, the patients are usually normal, with good social, occupational, and interpersonal skills. Unfortunately, as the disorder progresses the individual gradually becomes less able to perform socially and at work, and phobias and avoidance patterns develop that eventually lead to

these consequences. Therefore proper diagnosis and early intervention is crucial if the individual is to continue functioning at an acceptable level.

Treatments

Several treatments are currently available for anxiety disorders. These include pharmacotherapy, psychotherapy, analysis, and behavioral and cognitive therapies. These treatments, however, are not always available to patients for a variety of reasons, including access to resources, financial constraints, and patient suitability for some forms of treatment.

Benzodiazepine use has a number of benefits over these other forms of treatment. Compared with other medications they are less prone to abuse and addiction,³ as well as being relatively safe. In addition, they are readily available, inexpensive, and can begin to ameliorate the symptoms within days. An added bonus to the patient is the ability to face other issues complicating the illness, without overwhelming anxiety.

Risks of long-term use

When a patient is started on benzodiazepines, the initial goal is to find a dosage that is effective in reducing symptoms but is not associated with dose-related side effects. This treatment, though, is not without risk. It is essential for the prescribing physician to acknowledge these risks and discuss them fully with all potential candidates.

The most common side effect is sedation, which is a problem mainly during the initial phase of treatment. It has been demonstrated that all patients will develop some tolerance to sedation but not to the anxiolytic effects.⁸ When using these drugs one must warn patients of the associated problems of sedation, such as impaired concentration when driving, but also be aware that the aim is to find a dose without this side effect. Another related side effect is amnesia, which can be seen with benzodiazepines, especially with lorazepam (eg, Ativan) and triazolam (Halcion).⁹ Cognitive impairment is another side effect to which patients do not develop tolerance. As a general rule, the older a patient is, the lower the initial dose should be and the smaller the increments by which one increases the dose. If any evidence of cognitive impairment is seen, the dosage should

be reduced immediately and tapered off. Afterward one can offer a trial with an alternate benzodiazepine at the equivalent of a reduced dose.

Three areas of concern with long-term benzodiazepine treatment are drug abuse, drug dependence, and drug addiction. Drug abuse is defined as the intermittent use of certain substances for reasons other than intended, mainly for a euphoric effect, or in a harmful way. A number of studies have shown that benzodiazepines are not "enjoyable" and do not produce euphoric effects in patients with anxiety.¹⁰⁻¹⁶ In contrast, alcoholics and patients with a history of drug abuse have been found to prefer benzodiazepines over placebo.^{11-14,17} Clinical evidence from numerous studies demonstrates benzodiazepine abuse in alcoholics, users of several drugs, and opiate abusers.^{11,18-26} Table 1 lists characteristics of patients at high risk for developing benzodiazepine abuse and of patients who are abusing substances.

In contrast, drug dependence is characterized by the development of tolerance and physical dependence.⁸ Drug dependence and tolerance are not issues in patients with anxiety disorders treated with benzodiazepines.¹¹ A few physicians in Germany have reported isolated cases of tolerance in a small number of patients using benzodiazepines exclusively.²⁷⁻³⁰ However, most cases of tolerance have been documented in patients using the drugs in an abusive manner, ie, alcoholics or other drug abusers.

Physical dependence alone, however, does not imply drug dependence, but it is an important issue. Physical dependence is diagnosed by the presence of withdrawal symptoms upon cessation of a medication. This phenomenon has been extensively reported in the literature in relation to benzodiazepine use, even at recommended doses.³¹⁻³⁴ Recent evidence suggests that it is directly related to the duration of treatment and inversely related to the drug's half-life.^{35,36} It is essential to explain to the patient this concept and its consequences, ie, withdrawal symptoms can appear if the medication is discontinued abruptly. Symptoms include restlessness, tremor, agitation, sweating, insomnia, and in the severest form, grand mal seizures.

Drug addiction is the severest form of drug dependence and occurs when an individual develops a psychological as well as a physical dependence on a substance. Heroin and cocaine addiction are common examples of this form of dependence, in which the individual is dependent on the medication and abusing it at the same time.

Table 1. IDENTIFYING POSSIBLE DRUG ABUSE

FACTORS INCREASING THE RISK OF DRUG ABUSE

- History of substance abuse
- History of alcohol abuse
- Antisocial personality disorder
- Borderline personality disorder
- Alcoholic parents
- History of poor impulse control

CLUES TO POSSIBLE DRUG ABUSE

- Patient gives vague or inconsistent history
- Patient becomes demanding or aggressive during interview
- Patient refuses physical examination
- Patient demands certain drugs by name
- Patient refuses other treatments
- Patient refuses to allow others to be interviewed
- Patient continually loses prescriptions
- Patient does not attend regularly

Conclusion

Long-term benzodiazepine therapy is of benefit in certain anxiety disorders, ie, panic disorder with or without agoraphobia, agoraphobia, generalized anxiety disorder, and social phobia. Although other drugs are available, ie, tricyclics for panic disorder and buspirone (Buspar) for generalized anxiety disorder, many patients have no other options or do not respond and require long-term benzodiazepine treatment. Advantages of this approach include low cost, availability, rapid relief of symptoms, and effective therapy for most patients. This therapy is associated with certain risks, but if the drug is properly prescribed and monitored, these risks can be minimized. Safety measures include titrating doses,

especially in the elderly, close observation and follow up, and proper screening and education of patients.

For effective treatment of patients with anxiety disorder, a number of steps can help. If these steps are followed by the physician, they will aid in selecting the appropriate patients and reduce risks of therapy.

- Confirm the diagnosis of an anxiety disorder that is responsive to benzodiazepine treatment. Consider other treatments first, ie, buspirone for generalized anxiety disorder or tricyclics for panic disorder.
- Take a good history from the patient concerning past treatments and specifically ask about depression and past or present substance abuse. Seek collaborative evidence from other family members or previous doctors.
- Search for possible risk factors that put the patient at risk of abusing benzodiazepines, ie, antisocial or borderline personality disorders.
- If you have doubts about patient suitability for long-term therapy, refer the patient to an appropriate center or specialist.
- Discuss treatment options and the risks of long-term benzodiazepine therapy with your patient.
- Explain your expectations to the patient, ie, the need for close supervision initially, regular visits by the patient, and your reluctance to continue treatment if the patient is not willing to agree or comply with these rules.
- Fully educate the patient about how to use benzodiazepines properly and safely. This education should cover drug interactions, the need to keep the supply of medication safely hidden from others, and the necessity of medication charts, which should be brought with the patient to each consultation.
- Documentation is crucial. Explain the reasons for diagnosis and discuss alternative treatments. Keep thorough records of all prescriptions. ■

.....
Requests for reprints to: Dr Nicholas L.S. Potts, Department of Psychiatry, Duke University Medical Center, PO Box 3215, Durham, NC 27710 USA

References

1. IMS America Ltd. *National prescription audit*. Fort Washington, Pa: IMS Communications, Inc, 1987.

2. Food and Drug Administration. *Seventh annual review of drug utilization in the US - 1985*, 1985.
3. Schatzberg AF, Cole JO, editors. *Manual of clinical psychopharmacology*. Washington, DC: American Psychiatric Press, 1986.
4. Robins LN, Helzer JE, Weissman MM, Ocaschel H, Gruenberg E, Burke JD Jr, et al. Lifetime prevalence of specific psychiatric disorders in three sites. *Arch Gen Psychiatry* 1984;41:949-58.
5. Kaplan H, Sadock B. *Synopsis of psychiatry: behavioral sciences and clinical psychiatry*. 5th ed. Baltimore, Md: Williams and Wilkins, 1985:316-38.
6. Nagy A. Long-term use of benzodiazepines in psychiatric inpatients. *Acta Psychiatr Scand* 1987;76(1):64-70.
7. Fleischhacker WW, Barnas C, Hackenberg B. Epidemiology of benzodiazepine dependence. *Acta Psychiatr Scand* 1986;74(1):80-3.
8. DuPont RL. Abuse of benzodiazepines: the problems and the solutions. *Am J Drug Alcohol Abuse* 1988;14(Suppl):1-69.
9. Spitzer R, Williams J, editors. *Diagnostic and statistical manual of mental disorders*. 3rd ed, revised. Washington, DC: American Psychiatric Association, 1987.
10. Griffiths RR, Saunierud CA. Abuse of and dependence on benzodiazepines and other anxiolytic/sedative drugs. In: Smith DE, Wesson DR, editors. *The benzodiazepines: current standards for medical practice*. Lancaster, England: MTP Press Ltd, 1985:209-25.
11. Johanson CE, Uhlenhuth EH. Drug preference and mood in humans: Diazepam. *Psychopharmacology* 1980;71:269-73.
12. Johanson CE, Uhlenhuth EH. Drug preference in humans. *Federation Proc* 1982;41:228-33.
13. De Wit H, Johanson CE, Uhlenhuth EH. Reinforcing properties of lorazepam in normal volunteer subjects. *Drug Alcohol Depend* 1984;13:31-41.
14. De Wit H, Uhlenhuth EH, Johanson CE. Lack of preference for flurazepam in normal volunteers. *Pharmacol Biochem Behav* 1984;21:865-9.
15. DeWit H, Uhlenhuth EH, Johanson CE. Lack of preference in normal volunteers: effects of age and time of day. *Psychopharmacology* 1986;87(2):186-93.
16. DeWit H, Uhlenhuth EH, Hedecker D, McCracken SG, Johanson CE. Lack of preference for diazepam in anxious volunteers. *Arch Gen Psychiatry* 1986;43:533-41.
17. Department of Health and Human Services. Sedatives and anti-anxiety agents. In: Secretary, Department of Health and Human Services. *Drug abuse and drug abuse research. The second triennial report to Congress from the Secretary, Department of Health and Human Services*. Rockville, Md: Department of Health and Human Services; 1985:163-81. DHHS Publication No. (ADM)87-1486.
18. DuPont RL. *Benzodiazepines: the social issues - a guide for the physician*. Rockville, Md: Institute for Behavior and Health, Inc, 1986.
19. Craddock SG, Bray RM, Hubbard RL. *Drug use before and during drug abuse treatment: 1979-1981 TOPS Admission Cohort*. Rockville, Md: National Institute on Drug Abuse; 1985 Treatment Research Monograph Series, DHHS Publication No. (ADM)85-1387.

20. Hubbard RI, Bray RM, Craddock SG. Issues in the assessment of multiple drug use among drug treatment clients. In: Braude M, Ginzberg HM, editors. *Strategies for research on drugs of abuse*. Rockville, Md: National Institute on Drug Abuse, 1986.
21. Ball JC, Schaffer JW, Nurco DN. The day-to-day criminality of heroin addicts in Baltimore: a study into the continuity of offense rates. *Drug Alcohol Depend* 1986; 12:119-42.
22. Stitzer JL, Griffiths RR, McLellan AT, Grabowski J, Hawthorne JW. Diazepam use among methadone maintenance patients: patterns and dosages. *Drug Alcohol Depend* 1981; 8:189-99.
23. World Health Organization. *Report on the 6th WHO review of psychoactive substances for international control*. Geneva: World Health Organization, 1982.
24. Ladewig D. Abuse of benzodiazepines in western European society: incidence, prevalence, motives, and acquisition. *Pharmacopsychiatria* 1983;16(4):103-6.
25. DeWit H, Uhlenhuth EH, Johanson CE. Individual differences in reinforcing and subjective effects of amphetamine and diazepam. *Drug Alcohol Depend* 1986;16:341-60.
26. Heartzen CA, Martin WR, Ross FE, Neider GL. Psychopathic state inventory: development of a short test for measuring psychopathic states. *Int J Addict* 1981; 15:137-40.
27. Kemper N, Poser W, Poser S. Benzodiazepin-Abhängigkeit. *Dtsch Med Wochenschr* 1982; 105:1707-12.
28. Van Oefele K, Wolf B, Ruther T. Poster presentation at 4th International Congress Sleep Research, Bologna, Italy, July 18-22, 1983.
29. Ruther E, Hippus H. Neuroleptika in niedriger Dosierung als tranquilizer? *Munch Med Wochenschr* 1982;124:683-4.
30. Binder W, Kornhuber HH, Waiblinger G. Benzodiazepin - Sucht, unsere iatrogene Seuche: Faelle von Benzodiazepin-Abhängigkeit. *Off Gesundheitswes* Stuttgart: Georg Thieme Verlag, 1984.
31. Marks J. *The benzodiazepines: use, overuse, misuse, abuse*. Baltimore, Md: University Park Press, 1978.
32. Marks J. An international overview. In: Smith DE, Wesson DR, editors. *The benzodiazepines: current standards of medical practice*. Lancaster, England: MTP Press Ltd, 1985:67-86.
33. Busto U, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, SyKara K, et al. Withdrawal reaction after long-term benzodiazepines. *N Engl J Med* 1986;315:854-9.
34. Hallstrom C, Lader M. The incidence of benzodiazepine dependence in long-term users. *J Psychiatr Treatment Eval* 1982;4:293-6.
35. Covi L, Lipman RS, Pattison JH, Derogatis LR, Uhlenhuth EH. Length of treatment with anxiolytic sedatives and response to their sudden withdrawal. *Acta Psychiatr Scand* 1973; 49(1):51-64.
36. Rickels K, Case WG, Schweizer EE, Swenson C, Fridman RB. Low dose dependence in chronic benzodiazepine users: a preliminary report of 119 patients. *Psychopharmacol Bull* 1986;22(2):407-15.

ENTEX® LA

Prescribing Information

ACTIONS: Phenylpropanolamine hydrochloride is an α -adrenergic receptor agonist (sympathomimetic) which produces vasoconstriction by stimulating α -receptors within the mucosa of the respiratory tract. Clinically, phenylpropanolamine shrinks swollen mucous membranes, reduces tissue hyperemia, edema and nasal congestion, and increases nasal airway patency. Guaifenesin promotes lower respiratory tract drainage by thinning bronchial secretions, lubricates irritated respiratory tract membranes through increased mucus flow, and facilitates removal of viscous, inspissated mucus. As a result of these combined actions, sinus and bronchial drainage is improved, and dry, nonproductive coughs become more productive. **INDICATIONS:** Entex LA reduces swelling of nasal passages, helps decongest sinus openings and promotes nasal and/or sinus drainage. Entex LA helps drain bronchial tubes by thinning mucus and relieves irritated membranes in the respiratory passageways by preventing dryness through increased mucus flow. **CONTRAINDICATIONS:** Entex LA is contraindicated in individuals with known hypersensitivity to sympathomimetics, severe hypertension, or in patients receiving monoamine oxidase inhibitors. **WARNINGS:** Sympathomimetic amines should be used with caution in patients with hypertension, diabetes mellitus, heart disease, peripheral vascular disease, increased intraocular pressure, hyperthyroidism, or prostatic hypertrophy. **PRECAUTIONS:** Since this product is also available without a prescription, the following appears on the package labelling: This product should not be taken by persons who have high blood pressure, heart or thyroid disease, diabetes, persistent/chronic cough; or by pregnant/nursing women; or by persons taking high blood pressure medication or an antidepressant containing a monoamine oxidase inhibitor, except under the advice and supervision of a physician. Consult your physician if symptoms do not improve within 7 days or if you have peripheral vascular disease, glaucoma, or prostate disease. Do not exceed recommended dosage. Keep all medicines out of the reach of children. Do not crush or chew tablets. **Drug Interactions:** Entex LA should not be used in patients taking other sympathomimetics or monoamine oxidase inhibitors. **Drug/Laboratory Test Interactions:** Guaifenesin has been reported to interfere with clinical laboratory determinations of urinary 5-hydroxyindoleacetic acid (5-HIAA) and urinary vanillylmandelic acid (VMA). **Use in Pregnancy:** Animal reproduction studies have not been conducted with Entex LA. It is also not known whether Entex LA can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. Entex LA should not be used in pregnancy unless the potential benefits outweigh the possible risks. **Nursing Mothers:** It is not known whether the drugs in Entex LA are excreted in human milk. Because many drugs are excreted in human milk and because of the potential for serious adverse reactions in nursing infants, a decision should be made whether to discontinue nursing or to discontinue the product, taking into account the importance of the drug to the mother. **Use in Children:** Entex LA is not recommended for children under 6 years of age. **ADVERSE REACTIONS:** Possible adverse reactions include nervousness, insomnia, restlessness, dizziness, headache, nausea, or gastric irritation. These reactions rarely, if ever, require discontinuation of therapy. Chest tightness has been reported on occasion. Urinary retention may occur in patients with prostatic hypertrophy. **SYMPTOMS AND TREATMENT OF OVERDOSAGE:** The treatment of overdosage should provide symptomatic and supportive care. If the amount ingested is considered dangerous or excessive, induce vomiting with ipecac syrup unless the patient is convulsing, comatose, or has lost the gag reflex, in which case perform gastric lavage using a large-bore tube. If indicated, follow with activated charcoal and saline cathartic. Since the effects of Entex LA may last up to 12 hours, treatment should be continued for at least that length of time. **DOSAGE:** Adults and children 12 years of age and over - One (1) tablet twice daily (every 12 hours). Children 6 to under 12 years of age - One-half (1/2) tablet twice daily (every 12 hours). Entex LA is not recommended for children under 6 years of age. Tablets may be broken in half for ease of administration without affecting release of medication but should not be crushed or chewed prior to swallowing. **AVAILABILITY:** Entex LA is available as a blue, scored tablet imprinted "NE" and contains phenylpropanolamine hydrochloride 75 mg and guaifenesin 600 mg, in a special base to provide a prolonged therapeutic effect. Entex LA tablets are supplied in bottles of 100 and 24. Store below 30°C protected from moisture. Product Monograph available on request.

Norwich Eaton

Norwich Eaton Pharmaceuticals, Inc.
A Procter & Gamble Company
Cambridge, Ontario N1R 5W6
the registered trademark® owner

Benzac® W wash

Benzac® W Wash 5%, Benzac® W Wash 10%
Benzoyl peroxide - Acne therapy

INDICATIONS: Benzac® W WASH 5% and Benzac® W WASH 10% are topical aids for the treatment of acne vulgaris.

CLINICAL PHARMACOLOGY: The mechanism of action of benzoyl peroxide is not totally understood but its antibacterial activity against *Propionibacterium acnes* is thought to be a major mode of action. In addition, patients treated with benzoyl peroxide show a reduction in lipids and free fatty acids and mild desquamation (drying and peeling activity) with a simultaneous reduction in comedones and acne lesions.

Little is known about the percutaneous penetration, metabolism, and excretion of benzoyl peroxide, although it has been shown that benzoyl peroxide absorbed by the skin is metabolized, to benzoic acid and then excreted as benzoate in the urine. There is no evidence of systemic toxicity caused by benzoyl peroxide in humans.

CONTRAINDICATIONS: Known sensitivity to any of the components.

PRECAUTIONS: Avoid contact with eyes and mucous membranes. Observe patients carefully for possible local irritation or sensitivity during long-term topical therapy. Apply with caution on neck, circumoral and/or other sensitive areas. May bleach colored fabrics.

Radiation from ultraviolet and cold quartz sources as well as abrasion may add to the desquaming effect produced by benzoyl peroxide and, therefore, should be reduced in intensity and/or frequency.

ADVERSE REACTIONS: Allergic contact dermatitis and dryness have been reported with topical benzoyl peroxide therapy.

OVERDOSAGE: If excessive scaling, erythema or edema occur, the use of this preparation should be discontinued. To hasten resolution of the adverse effects, cool compresses may be used.

After symptoms and signs subside, a reduced dosage schedule may be cautiously tried if the reaction is judged to be due to excessive use and not allergenicity.

DOSAGE: Wash with Benzac W Wash 5% or 10% once or twice daily, avoiding contact with eyes and mucous membranes. Wet the area of application. Apply Benzac W Wash 5% or 10% to the hands and wash the affected areas. Rinse with water and dry. The degree of drying and peeling can be adjusted by modification of the dosage schedule.

SUPPLIED: Each 225g bottle contains: benzoyl peroxide 5% (Benzac W Wash 5%) or 10% (Benzac W Wash 10%) in sodium C14-16 olefin sulfonate, carbomer 940 and purified water.

REFERENCES:

- ¹ Data on file, Galderma Canada.
- ² Baker MD. Effects of Benzac W Wash on skin pH compared to Dial, Ivory and purpose soaps. Data on file, Galderma Canada. Sept. 1986.
- ³ Feaster JM. Evaluation of Benzac W Wash 10 in the reduction of *P. acnes* counts. Data on file, Galderma Canada. April 1987.

® Registered Trademark

CANADA
GALDERMA

The Future in Dermatology

2145 Meadowpine Blvd.
Mississauga, Ontario L5N 6R8
Tel: 1-416-826-0060
Telefax: 1-416-567-0592

PAAB
CCPP